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Objective: The prospective SONATA pivotal Investigational Device Exemption (IDE) trial
was performed in the United States (US) and Mexico to examine the safety and effectiveness
of transcervical fibroid ablation (TFA) in the treatment of symptomatic uterine fibroids. This
is an analysis of 12-month clinical outcomes in the US cohort.
Methods: TFA with the Sonata® System was performed on women with symptomatic
uterine fibroids. The 12-month co-primary endpoints were reduction in menstrual blood
loss and freedom from surgical reintervention. Symptom severity, quality of life, patient
satisfaction, safety, and reductions in uterine and fibroid volumes were also evaluated.
Results: One hundred twenty-five patients were enrolled and treated in the US. Both co-
primary endpoints were achieved in this US-based cohort, as 65.3% of patients reported
≥50% reduction in menstrual bleeding and 99.2% of patients were free from surgical
reintervention. Symptom improvement was noted by 97.4% of patients and 98.3% were
satisfied. Ninety-five percent of patients reported reduced menstrual bleeding at 12 months,
and 86.8% noted >20% reduction. Significant mean improvements at 12 months were
realized in both symptom severity and health-related quality of life (33.8 points and 45.8
points, respectively; all P<0.0001). Mean maximal fibroid volume reduction per patient was
63.8%. There was a 0% incidence of device related adverse events. Mean length of stay was
2.5 hrs and 50% of patients returned to normal activity within 1 day.
Conclusion: This analysis of US patients in the SONATA pivotal IDE trial demonstrates
results consistent with those in the full cohort. TFA with Sonata significantly reduced fibroid
symptoms with a low surgical reintervention rate through 12 months. These results support
the efficacy and safety of the Sonata system as a first-line treatment for women affected by
symptomatic uterine fibroids.
Keywords: uterine leiomyoma, transcervical fibroid ablation; TFA, radiofrequency ablation,
Sonata system
Introduction
The SONATA pivotal IDE trial (“SONATA trial;” ClinicalTrials.gov Identifier
NCT02228174) was a prospective, longitudinal, multicenter, single-arm trial of
transcervical fibroid ablation (TFA) with the Sonata® system in a cohort of
women with symptomatic uterine fibroids.1 The primary endpoints at 12 months
have been reported, and follow up is ongoing through 36 months. The overall trial
population of 147 women were made up of patients from the US (n=125) and
Mexico (n=22). Previous clinical results with the Sonata system demonstrated
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significant improvements in menstrual bleeding, quality of
life and overall symptom severity in conjunction with
excellent safety and surgical reintervention; total fibroid
volume was reduced by 62%-67% at 12 months.1,2 This
analysis examines the 12-month clinical outcomes of TFA
with the Sonata system in the US patient cohort from the
full SONATA trial.
Materials and methods
The Sonata system (Gynesonics, Inc; Redwood City, CA,
USA), which has received United States Food and Drug
Administration (FDA) clearance and Conformité
Européene (CE) Mark, has been described in detail.2–5
Previously known as VizAblate™, the Sonata system
(Figure 1) consists of a custom RF generator, a laptop-
based ultrasound system with custom Graphical Guidance
Software (GGS), and a single-use Radiofrequency
Ablation (RFA) Handpiece integrally combined with a
reusable Intrauterine Ultrasound (IUUS) Probe in a single
treatment device. This system provides the gynecologist
with a real-time, image-guided transcervical treatment
option. Therapeutic radiofrequency energy is delivered to
the fibroid according to a treatment cycle that is dependent
on ablation size. Each ablation is scalable and determined
graphically by the treating physician, maximizing the per-
centage of each fibroid to be ablated while avoiding ther-
mal injury to adjacent viscera. The anesthesia choice for
each patient may be individualized, as there is no require-
ment for general anesthesia; conscious sedation, and regio-
nal anesthesia (all with or without adjuvant paracervical
blockade) were options provided within the SONATA
clinical trial.
Premenopausal women between ages 25–50 with
symptomatic uterine fibroids associated with heavy
menstrual bleeding were eligible for the SONATA trial if
they had up to 10 myomata of International Federation of
Gynecology and Obstetrics (FIGO) types 1, 2, 3, 4, and/or
2-5 (transmural) between 1–5 cm in diameter, experienced
heavy menstrual bleeding as documented by a pictorial
blood loss assessment chart (PBAC) score between 150–
500, and had at least one fibroid that either indented
(FIGO types 1, 2, 2-5) or abutted (FIGO type 3) the
endometrial cavity. While type 5 and type 6 subserous
myomata did not count towards the total number of
fibroids, they could be ablated at the discretion of the
investigator. Women were excluded if they desired ferti-
lity, had type 0 fibroids 1 cm or larger, had multiple
endometrial polyps or any polyps ≥1.5 cm in diameter, a
history of endometrial or fibroid ablation, prior uterine
artery embolization (UAE), current tubal implants and
clinically significant adenomyosis or substantial fibroid
calcification.
Patients underwent screening that included transvagi-
nal sonography, contrast-enhanced magnetic resonance
(MR) imaging, assessment of menstrual bleeding via a
pictorial blood loss assessment chart (PBAC), symptoma-
tology and quality of life evaluation using the Uterine
Fibroid Symptom and Quality-of-Life (UFS-QoL)
Questionnaire, and a recording of baseline general health
status using the EQ-5D (EuroQoL) questionnaire. All
patients underwent cervical cancer and endometrial hyper-
plasia/carcinoma screening.
The US FDA approved the SONATA Investigational
Device Exemption (IDE) trial in the US. Approvals were
obtained from local and central institutional review boards
(Table S1) prior to patient enrollment. The research was
conducted according to the principles stated in the World
Medical Association Declaration of Helsinki. Each patient
provided her written informed consent to participate in the
trial. All studies and records had protected health informa-
tion deidentified.
The two co-primary endpoints of the SONATA trial, as
required by the FDA, consisted of menstrual bleeding
reduction at 12 months and freedom from surgical reinter-
vention due to heavy menstrual bleeding (HMB) through
12 months. Overall study success required meeting the
individual success criteria for both co-primary endpoints.
Each patient was considered to have had a successful
treatment outcome if she experienced ≥50% reduction in
PBAC score with the score being <250. In terms of study
success for this endpoint, the lower confidence limit (LCL)
of the percentage of patient success was ≥45%. For the
Figure 1 The Sonata treatment device, combining an intrauterine sonography
probe with a radiofrequency ablation handpiece into a single integrated handpiece.
Hudgens et al Dovepress
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surgical reintervention co-primary endpoint, patient suc-
cess was defined as a lack of surgical reintervention for
HMB due to treatment failure at 12 months, and its study
success criterion was a LCL of the percentage of patient
success ≥75%.
Secondary endpoints included patient safety, reduction
in total and perfused fibroid volumes at 12 months, change
in the symptom severity score (SSS) and health-related
quality of life (HRQOL) subscales of the UFS-QOL
Questionnaire, overall patient treatment outcome using
the Overall Treatment Effect (OTE) questionnaire, time
to return to normal activity, patient satisfaction, change
in general health outcome as determined by the EQ-5D
questionnaire, pain and tolerance of the procedure, mean
length of stay (LOS) and occurrence of pregnancy with
pregnancy outcome. Treated patients were followed at
10 days, 30 days, 3 months, 6 months and at 12 months,
with longer-term follow-up planned for 24 months and
36 months.
All statistical analyses were performed with SAS 9.3
(SAS, Cary, NC). Values were considered significant at the
level of α=0.05.
Results
Twenty-one clinical study sites in the US enrolled and
treated 125 patients. Baseline patient and fibroid charac-
teristics are provided in Table 1 and Table 2, respectively.
Mean age of enrolled patients was 43.4±4.0 years with a
mean body mass index (BMI) of 29.5±6.4 (kg/m2).
Patients were 48% White, 39% Black, and 17% Latina
(Table 1).
Three patients were excluded from the Full Analysis Set
population as they were diagnosed with menopause during
the 12 months after TFA with the Sonata system, with a
resultant inability to provide a PBAC diary at their 12-
month visits. Thus, the Full Analysis Set consists of 122
patients of the 125 patients. For the menstrual bleeding
reduction endpoint, 121 of the 122 patients were included
in this analysis, as one patient who underwent surgical
reintervention prior to her 12-month visit was excluded
from the analysis of this endpoint per the study statistical
analysis plan. For the surgical reintervention endpoint eva-
luation, all 122 patients in the Full Analysis Set were
included.
All 125 patients were treated in an outpatient setting,
including 7 physician practice offices and 4 ambulatory
care centers. Sixty-nine patients (55.2%) were treated in an
operating room, 33 (26.4%) received their procedures in
an ambulatory care center while 23 (18.4%) patients were
treated in a physician office. Seventy-four patients (59.2%)
received general anesthesia while 51 (40.8%) had their
procedures under conscious sedation. Paracervical block-
ade was co-administered as an ancillary local anesthetic
modality in 54 (43.2%) of patients. Mean length of stay
Table 1 Baseline Patient Characteristics
Characteristic Results
Age1, N 125
Mean ± SD 43.5 ± 4.0
Median 44.0
Min, Max 33, 50
Ethnicity, N 125
Hispanic or Latino 21 (16.8%)
Not Hispanic or Latino 104 (83.2%)
Race2, N 125
American Indian or Alaska Native 3 (2.4%)
Asian 2 (1.6%)
Black or African American 49 (39.2%)
Native Hawaiian or Other Pacific
Islander
1 (0.8%)
White 60 (48.0%)
Other 11 (8.8%)
BMI, N3 125
Mean ± SD 29.5 ± 6.4
Median 28.0
Min, Max 18.0, 49.8
Notes: 1Age in years. 2Subjects indicating multiple races are counted once under
each race. Percentages may add to more than 100%. 3Calculated for those with
both height and weight measurements (kg/m2)
Table 2 Baseline PBAC and Fibroid Characteristics, Full Analysis
Set (N=122)
Characteristic Results
PBAC, N 122
Mean ± SD 293.5 ± 96.1
Median 281.0
Min, Max 150.2, 498.3
Total Fibroid Volume (cc), N 117
Mean ± SD 72.3 ± 90.1
Median 38.9
Min, Max 0.8, 522.9
Total Uterine Volume (cc), N 122
Mean ± SD 272.9 ± 155.8
Median 234.4
Min, Max 80.7, 868.1
Dovepress Hudgens et al
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(including procedure time) was 2.5±1.3 hrs, with 91 of 125
patients (72.8%) having a length of stay ≤3 hrs. Median
length of stay was 2.3 hrs.
Nearly all patients (95%; 115/121) experienced some
reduction in menstrual bleeding at 12 months after TFA,
with 86.3% experiencing reduced menstrual bleeding by
3 months. Regarding the 12-month PBAC timepoint,
65.3% (79/121) of patients (95% CI 56.1–73.7%) reported
at least 50% reduction in menstrual bleeding, which met
the endpoint success criterion that the LCL of the 95% CI
be ≥45%. Detailed PBAC reduction results are provided in
Table 3.
The other co-primary endpoint, surgical reintervention
for heavy menstrual bleeding at 12 months post-ablation,
was also met. Only one patient underwent surgical inter-
vention (elective hysterectomy for abnormal uterine bleed-
ing) within the first 12 months of her post-treatment
course. Thus, 99.2% (95% CI 94.3–99.9%) of patients
were free from surgical reintervention for heavy menstrual
bleeding at 12 months after treatment with the Sonata
system. This outcome met the endpoint success criterion
that the LCL of the 95% CI be ≥75%. The percentage of
patients achieving either co-primary endpoint did not sig-
nificantly vary by ethnicity and were similar for White,
Black and Latina patients.
Treatment with the Sonata system resulted in significant
improvements in all patient-reported outcomes, beginning
with the 3-month visit (the first post-treatment visit that
included these questionnaires). As seen in Figure 2, patients
reported a mean SSS reduction of 33.8 points (N=115) at
12 months post-procedure (P<0.0001) and a mean increase
of 45.8 points in HRQOL (N=115; P<0.0001). Regarding
the OTE questionnaire, 97.4% of patients responding at
12 months (112/115) noted improvement in their fibroid
symptoms, while 1.7% (2/115) reported no change in symp-
toms and 0.9% (1/115) noted a worsening of symptoms.
Patients reported significantly improved health status
on the EQ-5D questionnaire at 12 months post-procedure.
Self-reported scores on the EQ-5D questionnaire range
from values of less than 0, representing health states
worse than “death”, to a maximum score of 1.0, represent-
ing “perfect health.” At baseline, US patients in the
SONATA trial had a mean overall health score of 0.73
(N=122). At 12 months (N=114), their mean EQ-5D score
rose to 0.90 (P<0.0001). Of note, health status signifi-
cantly improved as early as 3 months after treatment
with Sonata, with EQ-5D scores rose to 0.88 at 3 months
(n=118; P<0.0001).
Of 115 patients reporting at 12 months, 98.3% of
patients expressed satisfaction with their treatment, and
a similar percentage (96.5%) would also recommend
Sonata to a friend or family member. Specifically,
70.4% of reporting patients indicated that they were
“very satisfied” with treatment, 18.3% were “moderately
Table 3 Change in PBAC Score by Visit
PBAC Score Baseline 3 Monthsa Change % Change
N 121 117 117 117
Mean ± SD 293.9± 96.3 175.9 ± 110.3 -119.3 ± 116.0 -38.9 ± 39.1
Median 283.6 153.4 -113.0 -44.4
Min, Max 150.2, 498.3 11.7, 647.8 -395.2, 445.1 -96.5, 219.6
P <.0001 <.0001
6 Months Abs. Change % Change
N 121 121 121
Mean ± SD 146.3 ± 102.7 -147.6 ± 105.7 -50.0 ± 30.2
Median 114.9 -133.5 -56.1
Min, Max 11.7, 519.9 -469.5, 124.9 -94.8, 38.3
P <.0001 <.0001
12 Months Abs. Change % Change
N 121 121 121
Mean ± SD 141.3 ± 107.2 -152.6 ± 125.0 -50.2 ± 42.4
Median 130.7 -145.2 -58.1
Min, Max 0.0, 902.2 -491.9, 679.4 -100.0, 304.9
P <.0001 <.0001
Hudgens et al Dovepress
submit your manuscript | www.dovepress.com
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satisfied,” 9.6% were “somewhat satisfied,” 0.9% were
“somewhat dissatisfied,” and 0.9% were “moderately
dissatisfied” at 12 months. No patients were “very dis-
satisfied” with their treatment. Similarly, 82.6% (95/115)
would “definitely recommend” treatment with Sonata,
13.9% would “probably recommend” it, and 3.5%
would “probably not recommend” it at 12 months. No
patient indicated that she would “definitely not recom-
mend” the treatment.
Pain scores were evaluated on a scale from 0 (“No pain
sensation”) to 10 (“Most intense pain imaginable”). Mean
procedural pain scores were 0.01±0.1 for procedures under
general anesthesia (N=74) and 0.6±1.6 for procedures per-
formed under conscious sedation (N=51). Recovery pain
scores were 3.4±2.9 for patients receiving general anesthe-
sia and 2.5±2.7 for those who were treated under conscious
sedation. Overall, 98% (122/125) of patients found treat-
ment with the Sonata system to have been tolerable.
Specifically, 63.2% (79/125) of patients reported the proce-
dure to have been “Very Tolerable”, 32% (40/147) found the
procedure to be “Moderately Tolerable”, 2.4% (3/147) char-
acterized it as “Minimally Tolerable”, and 2.4% (3/147)
said it was “Intolerable”. Overall mean pain scores regard-
less of anesthesia choice were 0.2±1.0 (range 0.0–7.0) dur-
ing the procedure and 3.0±2.8 (range 0.0–10.0) during
recovery (reported from the time between procedure com-
pletion and discharge).
0
Baseline (n=122, 122) 3 months (n=120, 119) 6 months (n=118, 117) 12 months (n=115, 115)
10
20
30
40
50
60
70
80
90
100
54.3
40.6
24.8
20.5 20.3
86.786.2
80
SSS HRQOL
Figure 2 Improvements in uterine fibroid symptom and quality of life questionnaire subscales through 12 months in the FAS population (mean values). The SSS subscale
demonstrates symptom reduction whereas the HRQoL subscale denotes increases in health-related quality of life. The results on both subscales signify improvement (all
P<0.0001).
Table 4 Attributes of Ablated Fibroids*
Procedure Parameter
Treated Fibroid Diameter, N 392
<1 cm 20 (5.1%)
1 – 2 cm 144 (36.7%)
>2 – 3 cm 108 (27.6%)
>3 – 4 cm 69 (17.6%)
>4 cm 51 (13.0%)
Treated Fibroid Type, N 392
Type 1 13 (3.3%)
Type 2 76 (19.4%)
Type 2-5 70 (17.9%)
Type 3 102 (26.0%)
Type 4 89 (22.7%)
Type 5 39 (9.9%)
Type 6 3 (0.8%)
Number of Fibroids/Patient, N 125
Mean±SD 3.6 ± 2.2
Median 3.0
Min, Max 1.0, 10.0
Number of Treated Fibroids/Patient, N 125
Mean±SD 3.1 ± 2.2
Median 3.0
Min, Max 1.0, 9.0
Treated Fibroid Diameter (cm), N 392
Mean±SD 2.5 ± 1.2
Median 2.3
Min, Max 0.3, 6.5
Notes: *Determined via intrauterine sonography at the time of treatment
SD, standard deviation;
Dovepress Hudgens et al
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Table 4 summarizes characteristics of ablated fibroids.
The mean maximal reduction in total leiomyoma volume
per patient from baseline to 12 months was 63.8%
(N=109). Of the 121 patients included in the analysis of
the bleeding reduction co-primary endpoint, there were 33
patients (27.3%) for whom a type 3 myoma was the sole
qualifying fibroid type (ie, they did not have an indenting
fibroid such as a type 2 myoma). Of these 33 patients, 22
(66.7%) had at least a 50% reduction in PBAC score at
12 months. This is similar to the percentages of patients
with indenting fibroids who achieved a 50% or greater
reduction in PBAC score at 12 months (58.3%, 67.4%
and 63.0% for patients with at least one type 1 fibroid,
patients without any type 1 fibroids and at least one type 2
fibroid, and patients without any type 1 and type 2 fibroids
and at least one type 2-5 fibroid, respectively).
Patients reported returning to normal daily activities in 2.1
±2.3 days, and half of the patients returned to normal activity
the day following the procedure. Patients with employment at
the time of procedure indicated having returned to work 3.7
±2.6 days post-procedure on average, with half of the patients
returning to work within 3 days after the procedure. Patients
resumed a normal diet at 0.7±1.3 days, normal sleep at 0.8
±1.7 days, and normal urinary and bowel functions at 0.2
±0.7 days and 1.5±1.9 days, respectively.
There were no occurrences (0.0%) of device related
adverse events, serious or otherwise. There was 1 proce-
dure-related serious adverse events reported in a single
subject (0.8%). That single procedure-related serious
adverse event involved a deep venous lower extremity
thrombus diagnosed 15 days post-procedure, managed as
an outpatient without sequelae.
As shown in Table 5, the results of the US cohort from
the SONATA trial and that of the original cohort including
patients from Mexico are provided.
Discussion
TFA with the Sonata system provides a safe and effective
transcervical treatment for symptomatic uterine fibroids
that uses RF ablation to treat all types of nonpedunculated
fibroids.5 Because it contains an integral intrauterine sono-
graphy probe, Sonata can image, target and treat fibroids
that are not accessible to other transcervical methods such
as hysteroscopic morcellation or resectoscopy. Indeed, in
the SONATA clinical trial, 77.3% of treated fibroids in the
US cohort were not amenable to operative hysteroscopy,
including intramural, transmural and subserous myomata.
While it is true that some type 1 and type 2 submucous
myomata can be resected hysteroscopically, TFA obviates
the inconvenience involved in removal of the resultant
fibroid fragments, can address larger and deeper submu-
cous fibroids that are less amenable to resection, and can
be used in the same session to ablate other nonresectable
fibroids without the need to also employ a resectoscope.
The US cohort represents 85% of patients treated in the
SONATA trial, as 22 patients (15%) in the 147-patient
SONATA pivotal IDE trial were enrolled in Mexico.
Clinical outcomes for US patients in the SONATA trial
were consistent with those in the full (US+Mexico)
SONATA trial population. The US cohort results also
met both co-primary endpoints of the clinical trial.
Results from this US cohort of the SONATA trial as
well as those from the full trial are consistent with the
results of the previous FAST-EU trial, in which 64.6% of
patients (31/48) experienced a >50% reduction in men-
strual bleeding and reported a mean reduction of 35.3
points in their SSS, both at 12 months.1,3 In both the full
and US-only cohorts of the SONATA trial, 95% of
patients had bleeding reduction, with 86.3% of patients
experiencing bleeding reduction by 3 months. In the
overall SONATA cohort of 147 patients, there were two
Table 5 Outcomes of the Full and US-only Cohorts of the
SONATA Pivotal IDE Trial
Parameter SONATA
(US+Mexico)
SONATA
(US)
≥ 50% reduction in menstrual
bleeding at 12 months (%)
64.8 (N=142) 65.3 (N=121)
Freedom from surgical reinter-
vention at 12 months (%)
99.3 (N=143) 99.2 (N=122)
Mean SSS reduction at 12
months (points)
32.1 (N=135) 33.8 (N=115)
Mean HRQOL increase at 12
months (points)
43.7 (N=134) 45.8 (N=115)
Percentage of patients reporting
improvement in overall fibroid
symptoms (OTE questionnaire)
96.3 (N=135) 97.4 (N=115)
Mean return to normal daily
activities (days)
2.2 (N=139) 2.1 (N=118)
Mean return to work (days) 3.6 (N=111) 3.7 (N=96)
Mean length of stay (hours) 2.5 (N=147) 2.5 (N=125)
Percentage of patients at least
“Somewhat Satisfied” at 12
months
97.1 (N=135) 98.3 (N=115)
Percentage of patients who
would at least “Probably
Recommend” Sonata to a friend
or family member
97.1 (N=135) 96.5 (N=115)
Hudgens et al Dovepress
submit your manuscript | www.dovepress.com
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reported procedure-related serious adverse events, one in
Mexico and one in the US. There were no device related
adverse events, serious or otherwise in the full SONATA
or US cohorts. Patient satisfaction was similar in both
groups.
The SONATA clinical trial was noteworthy for its inclu-
sion of a wide variety of fibroid types (every FIGO fibroid
type other than pedunculated fibroids [types 0 and 7] are
treatable by the Sonata system) and increased number of
treatable fibroids/patient compared with the prior FAST-EU
clinical trial in Europe and Mexico.2,3 The SONATA trial
included a robust patient selection process to minimize
confounding factors, excluding patients with other etiolo-
gies of abnormal uterine bleeding such as anovulation and
bleeding disorders. Furthermore, the study included a mix
of patient-reported outcomes to complement the objective
reintervention and bleeding primary endpoints.
Patients who expressly desired fertility were excluded.
This was secondary to ethical reasons as SONATA was a
pivotal safety and effectiveness investigational study.
Nonetheless, the SONATA trial includes 3-year follow up
of patients and the reporting of any pregnancy outcomes
should they occur.
Conclusion
This analysis of US patients in the SONATA pivotal IDE
trial demonstrates results consistent with those in the full
cohort. TFA with Sonata significantly reduced fibroid
symptoms with a low surgical reintervention rate through
12 months. These results support the efficacy and safety of
the Sonata system as a first-line treatment for women
affected by symptomatic uterine fibroids.
Authors’ Data Sharing Statement
Will individual participant data be available (including
data dictionaries)? No.
What data in particular will be shared: Not available.
What other study-related documents will be available?
Not available.
When will data be available (start and end dates)? Not
applicable.
By what access criteria will data be shared (including
with whom, for what types of analyses, and by what
mechanism)? Not applicable.
Acknowledgments
David B Toub, MD, MBA, Medical Director of
Gynesonics, Inc, contributed to the preparation of this
manuscript. Taraneh G Farazi, PhD, Vice-President of
Clinical Affairs at Gynesonics contributed to the review
of this manuscript. QST Consultations, Ltd provided bios-
tatistical analysis for this study. The abstract of this paper
was presented at the 2019 ACOG Annual Clinical and
Scientific Meeting as a poster presentation. The poster’s
abstract was published in a supplement to the journal
Obstetrics & Gynecology (May 2019 - Volume 133 -
Issue - p 113S doi: 10.1097/01.AOG.0000558
838.56257.35 https://journals.lww.com/greenjournal/
Abstract/2019/05001/Transcervical_Radiofrequency_
Ablation_of_Uterine.391.aspx).
Disclosure
Joseph Hudgens reports he is one of the members at
Speakers Bureau for Applied Medical. Andrea S Lukes
reports grants from Gynesonics, Abbvie, Myovant, and
Bayer, during the conduct of the study. David A Forstein
reports grants from Gynesonics, Inc, during the conduct of
the study. The institutions of each author received research
support from Gynesonics, Inc. The authors report no other
conflicts of interest in this work.
References
1. Chudnoff S, Guido R, Roy K, Levine D, Mihalov L, Garza-Leal JG.
Ultrasound-guided transcervical ablation of uterine leiomyomas.
Obstet Gynecol. 2019;133:13–22. doi:10.1097/AOG.0000000000
003032
2. Brölmann H, Bongers M, Garza-Leal JG, et al. The FAST-EU
trial: 12-month clinical outcomes of women after intrauterine
sonography-guided transcervical radiofrequency ablation of uterine
fibroids. Gynecol Surg. 2016;13:27–35. doi:10.1007/s10397-015-
0915-3
3. Bongers M, Brölmann H, Gupta J, Garza-Leal JG, Toub D.
Transcervical, intrauterine ultrasound-guided radiofrequency ablation
of uterine fibroids with the VizAblate® system: three- and six-month
endpoint results from the FAST-EU study. Gynecol Surg. 2015;12:61–
70. doi:10.1007/s10397-014-0873-1
4. Garza-Leal JG, Toub D, León IH, et al. Transcervical, intrauterine
ultrasound-guided radiofrequency ablation of uterine fibroids with the
VizAblate system: safety, tolerability, and ablation results in a closed
abdomen setting. Gynecol Surg. 2011;8:327–334. doi:10.1007/s10397-
010-0655-3
5. Toub DB. A new paradigm for uterine fibroid treatment: transcervical,
intrauterine sonography-guided radiofrequency ablation of uterine
fibroids with the sonata system. Curr Obstet Gynecol Rep.
2017;6:67–73. doi:10.1007/s13669-017-0194-2
Dovepress Hudgens et al
International Journal of Women's Health 2019:11 submit your manuscript | www.dovepress.com
DovePress
393
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f W
om
en
's 
He
al
th
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
98
.1
42
.1
15
.1
24
 o
n 
07
-A
ug
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Supplementary material
International Journal of Women's Health Dovepress
Publish your work in this journal
The International Journal of Women’s Health is an international, peer-
reviewed open-access journal publishing original research, reports,
editorials, reviews and commentaries on all aspects of women’s
healthcare including gynecology, obstetrics, and breast cancer. The
manuscript management system is completely online and includes a
very quick and fair peer-review system, which is all easy to use.
Visit http://www.dovepress.com/testimonials.php to read real quotes
from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-womens-health-journal
Table S1 List of each Institutional Review Board (IRB)
Institution Name IRB
Arizona Gynecology Consultants Western Institutional Review Board, IRB
Advanced Women’s Health Institute Western Institutional Review Board, IRB
GW Medical Faculty Associates Western Institutional Review Board, IRB
Christiana Care Health System Christiana Care, IRB
KO Clinical Research Western Institutional Review Board, IRB
Virtus Research Consultants Western Institutional Review Board, IRB
University of Maryland School of Medicine University of Maryland-Baltimore, IRB
Wayne State University Physician Group Western Institutional Review Board, IRB
Mercy Clinic Western Institutional Review Board, IRB
University of Mississippi Medical Center University of Mississippi Medical Center, IRB
Women’s Wellness Clinic Western Institutional Review Board, IRB
Cooper University Hospital Cooper Health System, IRB
Bosque Women’s Care Western Institutional Review Board, IRB
Albert Einstein School of Medicine-Montefiore Biomedical Research Alliance of New York IRB (BRANY IRB)
Drexel University College of Medicine Western Institutional Review Board, IRB
Magee-Women’s Hospital Western Institutional Review Board, IRB
PRISMA Health Upstate Health Sciences South Carolina, IRB
Baylor Research Institute Baylor Research Institute, IRB
Willowbend Health and Wellness Western Institutional Review Board, IRB
Eastern Virginia Medical School Eastern Virginia Medical School, IRB
Virginia Mason Medical Center Western Institutional Review Board, IRB
Hudgens et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Women's Health 2019:11394
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f W
om
en
's 
He
al
th
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
98
.1
42
.1
15
.1
24
 o
n 
07
-A
ug
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
